Next Article in Journal
H2-M and H2-O as Targeting Vehicles for the MHC Class II Processing Compartment Promote Antigen-Specific CD4+ T Cell Activation
Previous Article in Journal
Is It All a Conspiracy? Conspiracy Theories and People’s Attitude to COVID-19 Vaccination
 
 
Review

Shooting at a Moving Target—Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development

1
Institute of Virology (IVM), University of Münster, 48149 Münster, Germany
2
Interdisciplinary Centre for Clinical Research (IZKF), Medical Faculty, University of Münster, 48149 Münster, Germany
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Ralph A. Tripp
Vaccines 2021, 9(10), 1052; https://doi.org/10.3390/vaccines9101052
Received: 27 August 2021 / Revised: 17 September 2021 / Accepted: 18 September 2021 / Published: 22 September 2021
Since late 2019 the newly emerged pandemic SARS-CoV-2, the causative agent of COVID-19, has hit the world with recurring waves of infections necessitating the global implementation of non-pharmaceutical interventions, including strict social distancing rules, the wearing of masks and the isolation of infected individuals in order to restrict virus transmissions and prevent the breakdown of our healthcare systems. These measures are not only challenging on an economic level but also have a strong impact on social lifestyles. Using traditional and novel technologies, highly efficient vaccines against SARS-CoV-2 were developed and underwent rapid clinical evaluation and approval to accelerate the immunization of the world population, aiming to end the pandemic and return to normality. However, the emergence of virus variants with improved transmission, enhanced fitness and partial immune escape from the first generation of vaccines poses new challenges, which are currently being addressed by scientists and pharmaceutical companies all over the world. In this ongoing pandemic, the evaluation of SARS-CoV-2 vaccines underlies diverse unpredictable dynamics, posed by the first broad application of the mRNA vaccine technology and their compliance, the occurrence of unexpected side effects and the rapid emergence of variations in the viral antigen. However, despite these hurdles, we conclude that the available SARS-CoV-2 vaccines are very safe and efficiently protect from severe COVID-19 and are thereby the most powerful tools to prevent further harm to our healthcare systems, economics and individual lives. This review summarizes the unprecedented pathways of vaccine development and approval during the ongoing SARS-CoV-2 pandemic. We focus on the real-world effectiveness and unexpected positive and negative side effects of the available vaccines and summarize the timeline of the applied adaptations to the recommended vaccination strategies in the light of emerging virus variants. Finally, we highlight upcoming strategies to improve the next generations of SARS-CoV-2 vaccines. View Full-Text
Keywords: SARS-CoV-2; vaccines; variants; vaccine safety; vaccine effectiveness; adverse effects; heterologous vaccination; breakthrough infection; long Covid; second generation vaccines SARS-CoV-2; vaccines; variants; vaccine safety; vaccine effectiveness; adverse effects; heterologous vaccination; breakthrough infection; long Covid; second generation vaccines
Show Figures

Figure 1

MDPI and ACS Style

Günl, F.; Mecate-Zambrano, A.; Rehländer, S.; Hinse, S.; Ludwig, S.; Brunotte, L. Shooting at a Moving Target—Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development. Vaccines 2021, 9, 1052. https://doi.org/10.3390/vaccines9101052

AMA Style

Günl F, Mecate-Zambrano A, Rehländer S, Hinse S, Ludwig S, Brunotte L. Shooting at a Moving Target—Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development. Vaccines. 2021; 9(10):1052. https://doi.org/10.3390/vaccines9101052

Chicago/Turabian Style

Günl, Franziska, Angeles Mecate-Zambrano, Selina Rehländer, Saskia Hinse, Stephan Ludwig, and Linda Brunotte. 2021. "Shooting at a Moving Target—Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development" Vaccines 9, no. 10: 1052. https://doi.org/10.3390/vaccines9101052

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop